Clinical trials: Peritoneal Metastases From Gastric Cancer
Gastric Cancer (GC), Peritoneal Metastases From Gastric Cancer
Retlirafusp Alfa Plus SOX and Intraperitoneal Nab-Paclitaxel for Advanced Gastric/GEJ Cancer With Malignant Ascites
To evaluate the efficacy and safety of retlirafusp alfa in combination with SOX chemotherapy and intraperitoneal nab-paclitaxel as first-line treatment for advanced gastric/gastroesophageal junction (GC/GEJ) adenocarcinoma with…
- Conditions
- Gastric Cancer (GC), Peritoneal Metastases From Gastric Cancer, Ascites, Malignant
- Trial name
- NCT07855757
- Testing
- Retlirafusp Alfa + SOX + Intraperitoneal Nab-Paclitaxel
- Where
- China
- Volunteers
- 5 people
- Sponsor
- Zhejiang Cancer Hospital
Peritoneal Carcinomatosis, Gastrointestinal Cancer
Cytoreductive Surgery(CRS) Plus Hyperthermic Intraoperative Peritoneal Chemotherapy(HIPC) With Cisplatin to Treat Peritoneal Carcinomatosis From Upper Gastrointestinal Cancer
The majority of patients with upper gastrointestinal cancer, such as gastric, biliary, or pancreatic carcinoma, present with metastatic disease, and have an extremely poor survival, irrespective the type of treatment modality.
- Trial name
- NCT01116791
- Testing
- Cytoreductive Surgery (CRS) plus Hyperthermic Intraoperative Peritoneal Chemotherapy with Cisplatin (HIPC)
- Where
- Belgium
- Volunteers
- 34 people
- Sponsor
- Baki Topal
Gastric Cancer Stage IV, Peritoneal Metastases From Gastric Cancer
LM-302 and S-1 Plus Intraperitoneal Paclitaxel With or Without Cadonilimab for Claudin 18.2-positive Gastric or Gastroesophageal Junction Adenocarcinoma With Peritoneal Metastasis: a Prospective, Exploratory Study
In this study, the investigators will use LM-302 and S-1 plus intraperitoneal paclitaxel with or without Cadonilimab to treat Claudin 18.2-positive gastric or gastroesophageal junction adenocarcinoma with peritoneal metastasis.
- Conditions
- Gastric Cancer Stage IV, Peritoneal Metastases From Gastric Cancer, Gastric or Esophagogastric Junction Adenocarcinoma
- Trial name
- NCT07556640
- Testing
- LM-302, S-1, paclitaxel, LM-302, Cadonilimab, S-1, paclitaxel
- Where
- China
- Volunteers
- 74 people
- Sponsor
- Ruijin Hospital
Peritoneal Metastases From Gastric Cancer
INTERACT Stomach-II
This is a phase II study conducted in three hospitals in the Netherlands (Erasmus MC in Rotterdam, Catharina Hospital in Eindhoven, and the Netherlands Cancer Institute in Amsterdam). A total of 55 patients will take part.
- Trial name
- NCT07133490
- Testing
- intraperitoneal chemotherapy
- Where
- 3 sites in Netherlands
- Volunteers
- 55 people
- Sponsor
- Erasmus Medical Center
Peritoneal Carcinomatosis, Peritoneal Metastases
Intraperitoneal Aerosolized Nanoliposomal Irinotecan (Nal-IRI) in Peritoneal Carcinomatosis From Gastrointestinal Cancer
The PIPAC NAL-IRI study is designed to examine the maximal tolerated dose of nanoliposomal irinotecan (Nal-IRI, Onivyde) administered with repeated pressurized intraperitoneal aerosol chemotherapy (PIPAC), in a monocentric, phase…
- Conditions
- Peritoneal Carcinomatosis, Peritoneal Metastases, Colorectal Cancer, Small Bowel Cancer
- Trial name
- PIPAC-NAL-IRI (NCT05277766)
- Testing
- PIPAC with Nal-IRI
- Where
- Belgium
- Volunteers
- 45 people
- Sponsor
- University Hospital, Ghent
Stomach Cancer, Colorectal Cancer
Trial of Cytoreductive Surgery and HIPEC in Patients With Primary and Secondary Peritoneal Cancers
Patients with primary peritoneal cancer or secondary peritoneal cancers from stomach, colorectal, appendiceal, and gynecological primary origin will be screened by pathology and staging to see if they are eligible to undergo…
- Conditions
- Stomach Cancer, Colorectal Cancer, Appendiceal Cancer, Ovarian Cancer
- Trial name
- NCT03604653
- Testing
- HIPEC, Mitomycin c, CDDP 50
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Holy Name Medical Center, Inc.
Peritoneal Metastases From Gastric Cancer
HIPEC and Systemic Chemotherapy Combined With Apatinib in Unresectable Peritoneal Metastases From Gastric Cancer
The prognosis of patients with unresectable peritoneal metastases from gastric cancer is poor. These patients may obtain survival benefit from radical gastrectomy and cytoreductive surgery (CRS).
- Trial name
- NCT03349827
- Testing
- exploratory laparoscopy or laparotomy, HIPEC, Systemic chemotherapy
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Wuhan University
Stomach Neoplasms, Colorectal Neoplasms
Surgery Plus Intraoperative Peritoneal Hyperthermic Chemotherapy (IPHC) to Treat Peritoneal Carcinomatosis
OBJECTIVES: Determine response and survival of patients with peritoneal carcinomatosis treated with cytoreductive surgery plus intraoperative peritoneal hyperthermic chemotherapy with cisplatin and mitomycin Assess the quality of…
- Conditions
- Stomach Neoplasms, Colorectal Neoplasms, Neoplasm Metastasis, Mesothelioma
- Trial name
- IPHC (NCT00454519)
- Testing
- cytoreductive surgery, intraoperative peritoneal hyperthermic chemotherapy with cisplatin and mitomycin
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Wuhan University
Gastric Cancer, Metastatic
A Clinical Study of BioTTT001 in Combination With SOX and Toripalimab in Patients With Gastric Cancer
This is a phase I, single arm, open-label clinical study of BioTTT001 in combination with SOX and Toraplizumab in patients with peritoneal metastases from gastric cancer.
- Trial name
- NCT06283121
- Testing
- BioTTT001 intraperitoneal infusion, SOX regimen, toripalimab
- Volunteers
- 30 people
- Sponsor
- China Medical University, China
Gynecologic Cancer, Gynecologic Neoplasms
Intravenous and Intraperitoneal Paclitaxel and Oral Nilotinib for Peritoneal Carcinomatosis
Background: Tumors that have spread to the lining of the abdomen from other cancers, such as cancer of the appendix, colon, or ovary, are called peritoneal carcinomatosis. In most cases, outcomes are poor.
- Conditions
- Gynecologic Cancer, Gynecologic Neoplasms, Peritoneal Carcinomatosis, Peritoneal Neoplasms
- Trial name
- NCT05185947
- Testing
- Paclitaxel, Nilotinib, ECG
- Where
- United States
- Volunteers
- 21 people
- Sponsor
- National Cancer Institute (NCI)
Gastric Cancer, Peritoneal Carcinomatosis
Efficacy of HIPEC Combined With Systemic Chemotherapy and CRS on Peritoneal Metastases From Gastric Cancer
This project is a multi-center, prospective, randomized controlled clinical observation the safety and efficacy that stage IV limited peritoneal metastasis of gastric cancer patients accept hyperthermic intraperitoneal…
- Trial name
- NCT03179579
- Testing
- HIPEC with neoadjuvant chemotherapy, Systemic chemotherapy
- Where
- China
- Volunteers
- 88 people
- Sponsor
- Shu-Zhong Cui
Gastric Cancer (GC), HIPEC
Hyperthermic Intraperitoneal Chemoperfusion (HIPEC) in Gastric Cancer
The study investigates the outcomes of hyperthermic intraperitoneal chemoperfusion (HIPEC) in combination with curative-intent gastrectomy in resectable locally-advanced and limited-metastatic (low peritoneal cancer index)…
- Conditions
- Gastric Cancer (GC), HIPEC, Peritoneal Metastases From Gastric Cancer, Hyperthermic Intraperitoneal Chemoperfusion
- Trial name
- G-PEC (NCT07313579)
- Testing
- curative-intent surgery + HIPEC
- Where
- Ukraine
- Volunteers
- 200 people
- Sponsor
- Ukrainian Society of Clinical Oncology